

Index

Quality assurance of pharmaceuticals, volumes 1 and 2

Notes: (1) Prefixed numbers to page references denote the volume number; for example, “bioequivalence 1.30, **1.64–65**, 2.68” refers to pages 30 and 64–65 in volume 1 and page 29 in volume 2. (2) Page numbers in **bold type** indicate definitions and main discussions; page numbers in *italics* refer to tables and other displays.

- accelerated stability studies 1.5–6,
1.43–44, 1.48, 1.49–50
test conditions 1.53, **1.53–54**
see also stability testing
- accuracy, analytical procedures
1.120–121, 1.123
- acidity
 - herbal medicines 1.35
 - tests for 1.118
 - WHO Certification Scheme 1.188,
1.193
- active ingredient, in herbal medicinal
product 2.128
- active pharmaceutical ingredients
 - definition **2.10**
 - GMP **2.58–66**
 - sterile 2.64
- addresses, WHO Certification Scheme
1.189, 1.190
- administration
 - licensing process **1.24–27**
 - quality assurance 1.08, 1.109
- adverse drug reactions, reports 2.148,
2.149
- advisory bodies, national drug
regulation **1.23**
- agencies
 - government drug control
1.109–110
 - quality enforcement 1.108–109
- air handling systems
 - for biological products 2.107
 - clean areas 2.100–101
 - enclosed areas 2.60
 - radioactive and non-radioactive
areas 2.132
 - to prevent cross-contamination 2.78
- air-cleanliness levels **2.88–90**
- airborne particulate classification 2.89,
2.90
- airlocks **2.10**, 2.86, 2.100
 - definition **2.10**
- alkalinity, tests for 1.118
- allergens 2.103
- analysts
 - national laboratories 1.155–156,
1.158
 - training programmes 1.227–235
- analytical procedures
 - characteristics **1.120–124**, 1.123
 - chemical reference substances **1.125–**
131
 - data presentation **1.120**
 - infrared spectrophotometry 1.117,
1.125–127, 1.131, **1.136–142**
 - residual materials 2.73
 - stability testing **1.54–55**
 - training programme 1.227–235
 - types of 1.123, **1.123–124**
 - see also* basic tests; stability studies;
tests
- analytical worksheets **1.166–167**,
1.168
- animals 1.158
 - care staff 2.105
 - quarters and care 2.31, **2.108**
- antibiotics 2.60
- antigens 2.103

- appeals procedures, GMP
 inspectorate 2.189–190
 applicants, WHO Certification Scheme 1.205
 application, definition 2.139
 asbestos-containing filters 2.98
 aseptic procedures 2.91, 2.97–98
 assay procedures 1.118, 1.126, 1.128, 1.168
 assessment 1.3–6
 herbal medicines 1.4, 1.31–37
 multisource products 1.66–69
 new products 1.21, 1.26
 pre-marketing 1.112–113
 safety 1.25, 1.29, 1.34–35
 see also quality assessment
 attenuated total reflectance (ATR) 1.141–142
 authorization 1.216, 1.217
 clinical trials 1.21–22
 narcotic/psychotropic substances 1.218–219
 new product licences 1.26
 pre-marketing assessment 1.112
 authorization holders, list 2.189
 authorized person 2.11, 2.27, 2.177
 definition 2.11, 2.177
 role and functions 2.3
 autoclaves 2.95, 2.133
 automated process controls and processing equipment 2.69
 available samples, definition 1.178

Bacillus anthracis 2.107
 basic tests 1.9–10, 1.111, 1.150–153
 objectives 1.150
 recommended methods 1.151–153
 batch
 definitions 1.48, 1.179, 1.205, 2.11, 2.160
 numbering 1.205
 test sampling 1.52–53
 batch certificates 1.114, 1.190, 1.192, 1.205
 imported drugs 1.213
 model 1.202–204
 batch control *see* batch certificates
 batch documentation, GMP 2.62–63
 batch number, definitions 2.11, 2.161
 batch records
 definition 2.11
 excipients 2.76–77
 GMP 2.44–46
 review 2.56
 batch size, for investigational products 2.121
 bioavailability 1.30, 1.64, 1.107
 multisource products 1.67–68, 1.69
 product non-approval 1.84–85
 “biobatch” production 2.68
 bioequivalence 1.30, 1.64–65, 2.68
 bioequivalence studies 1.74–80
 marketing authorization 1.69–70
 metabolite data 1.78
 results reporting 1.80
 statistics 1.79–80, 1.104
 symbols used 1.103
 biological control training programme 1.16, 1.229, 1.234–235
 biological indicators 2.94, 2.97
 biological preparations
 distribution and processing records 2.110–111
 quality assurance/quality control 2.111–112
 biological processes, inherent variability 2.104
 biological products
 GMP 2.3–4, 2.103–113
 in-process controls 2.111
 labelling 2.109–110
 premises and equipment 2.105–108
 WHO recommendations 1.107
 biological reference standards *see* reference standards
 biological substances, containers 2.107
 biological tissues, extraction of substances 2.103
 blending/mixing, in-process 2.79–80
 blinding operations, investigational products 2.123
 blood or plasma derivatives 2.103, 2.105, 2.107, 2.133
 British Standards Institution (BS 5750) 2.146
 buildings *see* premises
 bulk drug substances *see* active pharmaceutical ingredients
 bulk products 1.206
 assessment 2.123
 definition 2.11
 GMP 2.37
 instruments 1.127, 1.173
 quality control 2.54

- sampling 1.176
- specifications 2.41
- calibration, definition 2.11
- calorimetry, differential scanning 1.129
- campaign manufacture 2.106, 2.107
- Canada, *in vivo* equivalence study
 - requirements 1.89–102, 1.89
- carcinogenicity, herbal substances 1.29, 1.33
- cell banks, storage 2.106
- Certificate of a Pharmaceutical Product
 - see* product certificates
- certificates 2.112, 2.137
 - of analysis 1.169
 - reference substances 1.134
 - WHO Certification Scheme 1.190–204, 1.195–197, 1.200–201, 1.202–204
 - see also* product certificates
- Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce (WHO Certification Scheme) 1.1, 1.3, 1.7, 1.12–14, 1.27, 1.30, 1.143, 1.148, 1.178, 1.187–219, 2.2, 2.4, 2.9–10
 - abuse of scheme 1.194
 - certificate 1.190–204, 1.195–197, 1.200–201, 1.202–204
 - certifying authorities 1.206
 - counterfeit products 1.223
 - glossary and index 1.204–209
 - herbal medicines 1.34
 - implementation guidelines 1.187–219
 - imported drugs 1.107, 1.114, 1.210–211
 - multisource products 1.66
 - objectives 1.187–188
 - participation eligibility 1.188–189
 - WHO responsibility 1.194, 1.209
- changes
 - control, for excipients 2.77–78
 - post-marketing 1.85
 - revalidation after 1.112
 - significant 2.150
- changing *see* clothing
- charges, product certificates 1.191
- checklist
 - for inspection and preparation of report 2.169–173
 - for inspectors 2.150
- chemical control training programme 1.228, 1.231–232
- chemical reference standards *see* reference standards
- chemical reference substances *see* reference substances
- chiral drug substances 1.78
- chromatography 1.125, 1.130
 - equipment 2.109, 2.134
 - training 1.232
 - see also* gas-liquid chromatography; thin-layer chromatography
- clean areas
 - airborne particulate classification systems 2.90
 - classification 2.88–89
 - definition 2.11
 - personnel 2.98–100, 2.104–105, 2.131
 - premises 2.100–101
 - sanitation 2.87–88
 - sinks 2.106, 2.132
 - for sterile preparations 2.86
 - working conditions 2.106
 - working practices 2.92, 2.105, 2.131
- cleaning, of premises 2.30
- cleaning limits, residual materials 2.73
- cleaning procedures
 - investigational products 2.118
 - multipurpose equipment 2.72–73
 - validated 2.61
 - written 2.73
- cleanliness *see* hygiene; personal hygiene
- climatic zones 1.38, 1.47–48, 1.51–53, 1.51–52, 1.53
- clinical trials 1.72–74, 1.73–74, 2.4
 - authorization 1.21–22
 - complaints 2.117
 - definition 2.114–115
 - equivalence testing 1.70, 1.72, 1.82
 - on pharmaceutical products 2.113–124
 - protocols 1.74
 - reference products 2.118
 - selection of an appropriate dosage 2.114
- clinics, inspection 2.167, 2.173
- “closed” systems 2.133
- Clostridium botulinum* 2.107
- Clostridium tetani* 2.107

- clothing
 changing facilities 2.60, 2.99, 2.100
 disposable 2.99
 laundering or cleaning 2.99
 outdoor 2.99
 personnel 2.61
 protective 1.174, 2.61, 2.99
- coding systems, investigational products 2.121
- combination products 1.29, 1.36
- commingling, definition 2.70
- company documents 2.149
- competence, national authorities 1.189
- competent authorities, WHO
 Certification Scheme 1.206
- complaints 2.19–20
 dealing with 2.66
 excipients 2.71
 GMP 2.191, 2.196
 investigational products 2.117
 procedures 2.171
 records 2.149
 sampling 1.181
 in site master file 2.157
 spot checks 2.148
- component failures 2.211
- computer systems
 audit 2.85
 in control of manufacturing
 processes 2.76–77
 WHO drug registration package 1.3
- concentrations, tests for 1.123–124, 1.123
- conditions for sale and supply, inspection 2.171
- Conference of Experts on the Rational Use of Drugs, Nairobi (1985) 1.1, 1.15, 1.38, 2.1
- confidentiality 2.188–189
- confusion 2.17
- consignments
 acceptance sampling 1.182–186
 definitions 1.179, 2.12
- constituents with known therapeutic activity, definition 2.125
- consumers, counterfeit products 1.225–226
- containers
 biological substances 2.107
 effects on stability 2.83–84
 specifications 2.76
 sterile products 2.102
- contamination
 definition 2.12
 microbiological 1.119
 prevention during production 2.49–50
 samples 1.179
 tests for 1.129–131
see also cross-contamination
- continuous culture 2.112
- contract 2.22–23
 acceptor 2.22
 giver 2.21–22
 production and analysis 2.21–2.23, 2.157, 2.196
- control, definition 2.202
- control measure, definition 2.202
- controlled drugs 2.167
 definition 2.161
 diversion 2.171
- Convention for the Mutual Recognition of Inspection in Respect of the Manufacture of Pharmaceutical Products 1.188
- Convention on Psychotropic Substances (1971) 1.217, 1.218, 1.219
- conveyor belt, in clean area 2.101
- cooperation between firms 2.59
- corrective action 2.204, 2.208–209
 definition 2.202
- cosmetics 2.99
- counterfeit products 1.1, 1.15, 1.220–226, 2.5, 2.20
 definitions 1.216, 1.220, 2.161
 imported 1.214
 recommendations 1.222–226
- Counterfeiting Intelligence Bureau, International Chamber of Commerce 1.221
- critical control point (CCP) 2.203–204
 definition 2.202
 determination 2.207–208
- critical limits 2.203
 definition 2.202
 specification and verification 2.207–208
- critical operation, definition 2.12
- cross-contamination 2.17, 2.30
 avoidance/prevention 2.32, 2.33, 2.49–50, 2.78, 2.107
 definition 2.12
see also contamination
- crude plant materials 1.33
 definition 2.125

- culture media, GMP 2.38
- customs
 counterfeit products 1.223, 1.224
 imported drugs 1.211–215, 1.217–219
 storage facilities 1.215
- cytokines 2.103
- cytostatic substances, enclosed areas 2.60
- data
 presentation, analytical procedures 1.120
 verification 2.142
- date of manufacture 1.43
- decontamination systems 2.107
- defective products 2.19–20
 WHO Certification Scheme 1.194
- defects, dealing with 2.66
- defined storage instructions 1.43
- degradation
 basic tests 1.150–151
 during transit 1.107
 reference substances 1.133
 stability testing 1.4–6
see also deterioration
- delivery, definition 2.12
- design
 bioequivalence studies 1.76–77, 1.103
 stability studies 1.51, 1.52–54
- design qualification (DQ) 2.19
- destruction, of unused investigational products 2.124
- detection, limit of 1.122, 1.123
- detergents 2.87
- deterioration
 drug products 1.39–40
 inadequate storage 1.38
see also degradation
- developing countries
 counterfeit products 1.224
 drug analysis training programme 1.227–235
 drug control 1.2–3, 1.18–30
 drug production 1.13
 health budgets 1.1
The international pharmacopoeia 1.7–8
 national laboratories 1.10–12, 1.154–162
 training fellowships 1.235–238
- development
 basic tests 1.151–153
 laboratory services 1.162
see also product development
- deviation, definition 2.202
- diagnostic agents for *in vitro* use 2.103
- differential scanning calorimetry 1.129
- diffuse reflectance techniques 1.142
- disinfectants 2.87
- distribution 1.7, 1.105–115
 channels 2.5, 2.157–176
 drug stability 1.4–5
 inspection 2.5, 2.157–176, 2.160–163, 2.167
 packaging and storage 1.107
 quality surveillance 1.114–115
 records
 biological preparations 2.110–111
 radiopharmaceuticals 2.136
 reference substances 1.135
 in site master file 2.157
- distributors
 counterfeit products 1.224
 licences 1.21
 responsibilities 1.107
- documentation
 analytical 2.144
 on company to be inspected 2.149
 excipient manufacture 2.75–77
 GMP 2.40–48, 2.61–63, 2.182–183, 2.196
 HACCP 2.210
 herbal medicines 2.126–128
 imported products 1.213
 investigational products 2.119–121
 licensing 1.27
 multisource products 1.68–69
 reference substances 1.133–134
 in site master file 2.157
 therapeutic equivalence 1.69–70, 1.71
 WHO Certification Scheme 1.190–204, 1.195–197, 1.200–201, 1.202–203
- dosage forms 1.65, 1.206
 bioavailability 1.64
 in clinical trials 2.114, 2.116
 drug degradation 1.4
 equivalence studies 1.88, 1.89–102
 equivalent 2.143
The international pharmacopoeia 1.117–119, 1.127
 quality specifications 1.110–111
 sampling 1.182–183
 solid oral 2.143
 stability 1.4–5, 1.37–46
 deterioration factors 1.39–40

- less stable substances 1.44–45
 - testing guidelines 1.46–56
 - testing training 1.232
 - verification 1.153
- drainage 2.33
 - see also* sinks and drains
- drug analysis, training programmes 1.227–235
- drug control agencies 1.108, 1.109–110
- drug control laboratories 1.154–174
 - instruments and their calibration 1.172–173
 - organizational structure 1.164
 - reagents 1.170–172
 - reference materials 1.172
 - safety 1.173–174
 - samples handling 1.165–169
 - specifications repertory 1.170
 - staffing 1.164–165, 1.227
 - training programme 1.227–235
 - see also* laboratory services
- drug control systems 1.1, 1.18–30
 - government agencies 1.108, 1.109–110
 - government laboratories 1.162–174
 - imported drugs 1.211, 1.212–214, 1.217–219
 - national 1.106
 - national laboratories 1.154–162
 - provisional registration 1.24–25
 - see also* regulation; regulatory authorities
- drug distribution *see* distribution
- drug inspector *see* inspector
- drug legislation *see* legislation
- drug master file, definition 2.70
- drug regulatory authorities *see* regulatory authorities
- drug substance, physical characteristics and specifications 2.143
- drugs
 - classification 2.160
 - definitions 1.106, 2.161
 - nomenclature 1.113
 - side-effects and toxicity 2.160
- eating, drinking, and smoking facilities 2, 61, 2.60
- education
 - counterfeit products 1.225–226
 - patients 1.42
 - see also* qualifications; training
- efficacy
 - drugs 1.106–107
 - herbal medicines 1.35–36
- electronic data-processing systems 2.62–63
 - see also* computer systems
- eligibility, WHO Certification Scheme 1.188–189
- enclosed areas, for special purposes 2.60
- endotoxin/pyrogen free *see* sterile
- endotoxins, monitoring 2.109
- environmental hazards 2.211
- environmental monitoring 2.117
- enzymes 2.103
- equipment
 - biological products 2.105–108
 - calibration 1.127, 1.172–173, 2.61
 - for chromatography 2.109, 2.134
 - clean areas 2.101–102
 - cleaning and maintenance 2.60, 2.61, 2.72
 - critical 2.134
 - defective 2.61
 - excipients 2.72–73
 - GMP 2.34, 2.60–61, 2.195
 - investigational products 2.117–118
 - maintenance record 2.77
 - multipurpose 2.60, 2.72, 2.73
 - national laboratories 1.156, 1.156, 1.158–160, 1.159
 - new or changed 2.143, 2.150
 - radiopharmaceuticals 2.132–133
 - sampling procedures 1.179–180
 - in site master file 2.156
- equivalence, pharmaceutical 1.66
- equivalence studies
 - clinical interchangeability 1.67–68
 - marketing authorization 1.69–72
 - national requirements 1.88–102, 1.89–102
 - types of 1.72–83
 - when not necessary 1.70–71
 - see also* interchangeability
- errors, human and organizational 2.212
- escort, for inspector 2.149, 2.151
- essential drugs 1.1, 1.58–60
- established ingredients, product licensing 1.27–28
- ethics, clinical trials 1.73
- ethylene oxide 2.96
- eukaryotic cells, growth of strains 2.103

- European Community, stability testing guidelines 1.57
- European Organization for Quality Control, stability testing guidelines 1.57
- European Standard EN 45012 2.177
- evaluation
 - reference substances 1.127–131
 - stability testing 1.54
 - test results 1.169
- examples
 - inspection report 2.6
 - Model Batch Certificate of a Pharmaceutical Product 1.202–204
 - Model Certificate of Good Manufacturing Practices 2.197–199
 - Model Certificate of a Pharmaceutical Product 1.195–199
 - Model Essential Drugs stability survey answer sheet 1.58–60
 - Model Statement of Licensing Status of Pharmaceutical Products 1.200–201
 - receipt form 2.175–176
 - stability testing summary sheet 1.61
 - stability testing survey answer sheets 1.58–60
- excipient manufacture
 - ISO 900 series certification 2.69
 - water systems/water quality 2.81–82
- excipient manufacturer
 - inspection 2.71–72
 - responsibilities 2.68–70
- excipients
 - batch production records 2.76–77
 - definition 2.71
 - delivery 2.82
 - documentation 2.75–77
 - equipment 2.72–73
 - expiry dates 2.84
 - GMP 2.66–85
 - good production practices 2.78–82
 - importance 2.67–68
 - packaging operations 2.82
 - processing steps 2.69
 - quality control 2.82–85
 - retention samples 2.83
 - returned 2.75
 - specifications 2.76
 - stability studies 2.83–84
 - sterile 2.71, 2.80–81
 - storage 2.75
- Expert Committees
 - Biological Standardization 1.107–108, 1.158, 2.3, 2.104
 - Essential Drugs 1.2
 - Nonproprietary Names 1.113
 - Specifications for Pharmaceutical Preparations 1.1–12, 1.14–15, 1.38, 2.1–2, 2.3, 2.4, 2.5, 2.9, 2.177
 - basic tests 1.150
 - laboratory services 1.154–155, 1.227–228
 - quality assurance 1.105–106, 1.110, 1.111
- expired stock *see* time-expired stock
- expiry dates 1.4, 1.5, 1.42, 1.48
 - drug stability 1.38–39
 - excipients 2.84
 - labelling 1.115
 - reference substances 1.134
 - time-expired stock 1.40
- explosions 2.211
- export authorization, narcotic/psychotropic substances 1.218–219
- exported products, WHO Certification Scheme 1.20, 1.189, 1.190–191
- exporting countries, responsibilities, multisource products 1.66, 1.67
- face mask 2.99
- facilities, new or changed 2.143, 2.148, 2.150
- failures, common 2.211–212
- feasibility studies, national laboratories 1.161–162
- fellowships, IFPMA quality control training 1.235–238
- fermentation products 2.103
- fibres, shedding 2.92, 2.98, 2.99
- final samples, definition 1.178
- finished products
 - assessment 2.123
 - definitions 1.206, 2.12, 2.161
 - GMP 2.37
 - herbal medicines 1.34
 - quality control 2.54
 - specifications 2.43
 - stability 1.39, 1.40, 1.46–56
 - test records 2.55

- fires 2.211
- first-stage national laboratory 1.155–156, 1.156
- fixed-ratio combination products 1.29
- flow diagram 2.201, 2.202, 2.206
- follow-up
- regulatory/administrative decisions 2.144–145
 - visits 2.148
- Food and Drug Administration (USA), stability testing guidelines 1.57
- formulations
- drug stability 1.40, 1.47
 - major modifications 1.50
- Fourier transform infrared spectrometers (FTIRs) 1.137
- freeze drying 2.134
- frequency, of product testing 1.54
- frequency scale, infrared spectrophotometry 1.137
- FTIRs *see* Fourier transform infrared spectrometers
- gas-liquid chromatography (GLC) 1.118, 1.130, 1.131
- see also* chromatography; thin-layer chromatography (TLC)
- General Agreement on Tariffs and Trade (GATT), counterfeiting 1.222
- generic products 1.29–30, 1.75
- definition 1.65
 - interchangeability 1.6, 1.30
 - procurement 1.3
 - see also* multisource products
- genetic phenotyping 1.75
- Germany
- in vivo* equivalence study requirements 1.89–102, 1.89
 - legal status of investigational products 2.113
 - stability guidelines 1.57
- global workshops, counterfeit drugs 1.15
- glossaries
- distribution channel inspection 2.160–163
 - drug stability 1.42–44, 1.48–49
 - excipients 2.70–71
 - GMP 2.10–15
 - HACCP 2.202–203
 - herbal medicines 2.125–129
 - import procedures 1.216–217
 - inspectorate 2.160–163
 - investigational products 2.114–115
 - multisource products 1.64–66
 - pre-approval inspections 2.139–140
 - quality system requirements 2.177–178
 - sampling 1.177–179
 - WHO Certification Scheme 1.204–209
- gloves 2.99
- see also* protective clothing
- GLP *see* good laboratory practice (GLP)
- GMP *see* good manufacturing practice (GMP)
- good clinical practice (GCP) 2.16, 2.113, 2.202
- good laboratory practice (GLP) 1.162–174, 2.16, 2.202
- good manufacturing practice (GMP) 1.6, 1.111–112, 1.187–188
- compliance 2.59, 2.139, 2.142, 2.145, 2.147
 - definition 2.161
 - and HACCP 2.201–202
 - inspection report guidance 2.193–199
 - inspectorate *see* inspectorate
 - interchangeability 1.63, 1.66
 - model certificate 2.6, 2.197–199
 - non-compliance 2.147, 2.150, 2.152, 2.153
 - for pharmaceutical products 2.17–18, 2.158–159
 - starting materials 2.58–85
 - status 2.9
 - web page 2.9
 - WHO Certification Scheme 1.190
 - WHO guidelines 2.2–4
- good pharmacy practice 1.7
- definition 2.161
- government inspectorate *see* inspectorate
- governments
- counterfeiting 1.222
 - drug control agencies 1.109–110
 - drug control laboratories 1.110, 1.162–174
 - drugs budgets 1.1
- gravimetric methods, training 1.231
- guidance
- counterfeit products 1.220–226
 - The international pharmacopoeia* monograph preparation 1.116–119
- guidelines
- analytical validation 1.119–124
 - basic tests 1.150–153

- chemical reference substances 1.124–136
- GLP, drug control laboratories 1.11–12, 1.162–174
- GMP 1.6
- herbal medicines assessment 1.4, 1.31–37
- import procedures 1.14, 1.210–215
- infrared spectrophotometry (general recommendations) 1.136–149
- multisource product interchangeability 1.6, 1.62–104
- national laboratories 1.154–162
- quality assurance in supply systems 1.105–115
- sampling procedures 1.12, 1.175–186
- stability of drug dosage forms 1.37–46
- stability testing 1.4–5, 1.46–61
- WHO Certification Scheme 1.13–14, 1.187–210
- guiding principles, small national drug regulatory authorities 1.2–3, 1.18–30
- HACCP *see* hazard analysis and critical control point (HACCP)
- hair, covering 2.99
- handling procedures
- drug stability 1.41
 - reference substances 1.131–134
- hazard
- definition 2.203
 - examples 2.210–211
- hazard analysis 2.6, 2.10, 2.203, 2.206–207
- definition 2.203
- hazard analysis and critical control point (HACCP)
- documentation and record keeping 2.210
 - glossary 2.202
 - methodology 2.6, 2.200–212
 - plan 2.203
 - system, guidelines 2.204
 - team 2.205
 - training and education 2.204–205
 - verification procedures 2.209–210
- hazardous chemicals 2.200, 2.210
- hazardous waste 2.211
- headgear 2.99
- health care professionals, counterfeit products 1.224
- health monitoring, test subjects 1.75
- heavy metals, tests for 1.118
- HEPA filters *see* high-efficiency particulate air (HEPA) filters
- hepatitis B vaccination 2.105
- herbal medicines 1.31
- assessment 1.4, 1.31–37
 - combination products 1.36
 - definitions 2.125
 - documentation 2.126–128
 - efficacy assessment 1.35–36
 - finished product specifications 2.128
 - GMP 2.4, 2.125–129
 - licensing 1.25
 - long-term use 1.32–33, 1.34, 1.35
 - premises 2.126
 - processing instructions 2.128
 - quality assessment 1.33–34
 - quality control 2.129
 - safety assessment 1.25, 1.29, 1.34–35
 - stability tests 2.129
 - starting materials 2.126–127
 - toxicological studies 1.34
- herbicides 2.78
- high-efficiency particulate air (HEPA) filters 2.89, 2.95
- high-performance liquid chromatography (HPLC) 1.118, 1.130
- homogeneity
- basic tests 1.151–153
 - definition 1.176
- hormones 2.60, 2.103
- hospital radiopharmacies 2.130
- hospitals, inspection 2.167
- HPLC *see* high-performance liquid chromatography
- humidity
- infrared spectrophotometry 1.138
 - protection of instruments 1.172–173
 - storage 1.132
- hybridoma techniques 2.103
- hydrogen peroxide vapour 2.96
- hygiene 2.18, 2.60, 2.61, 2.196
- see also* personal hygiene
- ICRS *see* International Chemical Reference Substances
- identity testing 1.123–124, 1.123, 1.150
- infrared spectrophotometry 1.128, 1.140–141
 - reference substances 1.127, 1.128

- IFPMA *see* International Federation of Pharmaceutical Manufacturers Associations
- immune sera 2.103
- immunoglobulins 2.103
- implementation, control laboratory projects 1.161–162
- import authorities, definition 1.216
- import controls 1.211, 1.212–214, 1.217–219
- importation 1.14, 1.210–219
definition 1.216
- imported products
consignment sampling 1.182
exporting country responsibilities 1.66, 1.67
generic 1.30
guidelines on procedures 1.210–215
herbal medicines 1.34
legislation 1.211–213
port of entry procedures 1.114–115
quality assessment 1.107, 1.108
quality surveillance 1.114
stability 1.4, 1.38
WHO certification scheme 1.107, 1.114, 1.189, 1.190–191
- importers
definition 1.216
guidelines for agents 1.190
inspection 2.172
notifiable medicinal products 1.24
responsibilities 1.107
- impurities
dosage forms 1.117–118
tests for 1.123–124, 1.123, 1.129–131
see also contamination; cross-contamination
- in vitro* dissolution studies 1.70, 1.72, 1.82–84
- in vivo* studies
national requirements 1.88–102, 1.89–102
therapeutic equivalence 1.67–68, 1.71–72, 1.74–82
- in-process blending/mixing 2.79–80
- in-process control
biological products 2.111
definition 2.12
records 2.55
- in-process testing, quality control 2.82
- independent analysis, samples 1.14
- industrially manufactured
pharmaceuticals, sampling procedures 1.12, 1.175–186
- information
reference substances 1.133–134
see also product information
- information exchange
counterfeit products 1.221, 1.223
multisource products 1.66
national regulatory authorities 1.19, 1.66, 1.69
reference substances 1.136
- information sources
clinical trials 1.22
drug registration software 1.3
good pharmacy practices 1.7
laboratory equipment 1.11
manufacturers 1.132
narcotic/psychotropic substances 1.218
nonproprietary names 1.113
quality assurance 1.2, 1.9
reference substances 1.9
UN 1.218
WHO Certification Scheme 1.14, 1.189, 1.190
- infrared reference spectra 1.9, 1.141, 1.148–149, 1.149
- infrared spectrophotometry 1.117, 1.125–127, 1.131
apparatus 1.137
environment 1.138
frequency scale 1.137
general recommendations 1.136–149
identification by 1.140–141
list of available reference spectra 1.148–149
reflectance techniques 1.141–142
solvents use 1.138
substance preparation 1.138–140
see also spectrophotometry; ultraviolet spectrophotometry
- injectable products, testing 2.87
- INN *see* International Nonproprietary Name
- innovator products 1.65
- insecticides 2.78
- inspection 2.139–199
announced 2.149, 2.165
by an external body or person 2.186, 2.187
comprehensive 2.165
concise 2.147, 2.149, 2.166

- of counterfeit, spurious or substandard products **2.174–175**
- of distribution channels 2.5, **2.157–176**
- facilities required 2.186
- follow-up 2.148, 2.149, 2.166
- frequency and duration **2.148–149**, 2.166
- government control laboratories 1.163
- investigative 2.166
- of manufacturing and quality control facilities 2.4–5
- methods **2.165–166**
- of pharmaceutical manufacturers 2.145–157
- of premises 2.170
- preparing for 2.149
- procedures **2.149–151**, **2.184–186**
- process **2.147–154**
- quality systems principles 2.5
- routine 2.147, 2.149, 2.165
- sampling during 1.181, 2.151
- skills required 2.159
- SOPs 2.167
- special 2.148, 2.149, 2.166
- team, composition 2.71, 2.141
- types 2.169
- unannounced 2.149, 2.166
- visual records 2.151
- see also* self-inspection
- inspection reports 2.149, **2.152**, 2.185–186
 - exchange between countries 2.188
 - form and content **2.154–157**
 - guidance on **2.193–199**
 - model lay-out 2.6
- inspector
 - access to premises, documents, or information 2.151
 - in national drug regulatory authorities 2.159
 - qualifications **2.163–164**
 - reference/information sources 2.166
 - role **2.146–147**, 2.149
 - training material 2.10
 - use of checklists 2.150
- inspectorate
 - appeals procedures 2.189–190
 - complaints procedures **2.191**
 - documentation **2.182–183**
 - follow-up regulatory/administrative decisions **2.144–145**
 - functions 1.109
 - government body 2.146
 - impartiality 2.178
 - mutual recognition 2.177
 - organizational structure 2.178, **2.179–181**
 - personnel **2.181–182**
 - see also* inspector
 - powers 2.186
 - publications 2.189
 - recalls and withdrawals procedure **2.191**
 - recommended procedure 2.178–179
 - records **2.183–184**
 - role and functions 2.160, **2.163–164**
 - terms of reference **2.179**
- installation qualification (IQ) 2.19
- instructions, storage conditions 1.43
- instruments **1.172–173**
 - analysis training programme 1.228
 - calibration 1.127, **1.172–173**
 - national laboratories **1.158–160**, 1.159
- intellectual property rights
 - counterfeiting 1.221, 1.222
 - interchangeable products 1.64
- interchangeability
 - multisource products 1.6, 1.30, **1.62–104**
 - see also* *equivalence studies*
- intermediate products
 - definition **2.12**
 - GMP **2.37**, **2.63**
 - quality control 2.54
 - specifications 2.41
- internal audit 2.145, 2.146
 - GMP inspectorate 2.190–191
 - reports 2.149
- International Atomic Energy Agency (IAEA) 2.4
- International Chamber of Commerce, Counterfeiting Intelligence Bureau 1.221
- International Chemical Reference Substances (ICRS) 1.9, **1.135–136**, **1.142–148**, 1.143–148
- International Conference of Drug Regulatory Authorities (ICDRA) 1.32, 1.63
- International Conference on Harmonisation, stability testing guidelines 1.58

- International Conference on Primary Health Care, Alma-Ata (1978) 1.1, 1.32, 2.1
- International Federation of Pharmaceutical Manufacturers Associations (IFPMA) 1.224
- fellowships 1.235–238
- International Infrared Reference Spectra 1.9, 1.141, 1.148–149, 1.149
- International Narcotics Control Board (INCB) 1.218, 1.221–222
- international narcotics rings, medicine counterfeiting links 1.221–222
- International Nonproprietary Name (INN) 1.113, 2.10
- International Organization for Standardization (ISO), 9000 series standards 2.5, 2.67, 2.69, 2.89, 2.146, 2.177
- International Pharmaceutical Federation 1.7
- The international pharmacopoeia* 1.2, 1.7–9, 1.116–149, 2.1, 2.2, 2.9
- international trade, pharmaceuticals 1.12–14, 1.187–219
- intrinsic thermodynamic properties, analytical methods 1.129
- investigational products 2.113–124
- batch records 2.121
 - batch size 2.121–122
 - blinding operations 2.123
 - cleaning procedures 2.118
 - coding (randomization) systems 2.121
 - definition 2.115
 - documentation 2.119–121
 - GMP 2.4, 2.113–114
 - inspection procedures 2.142
 - labelling instructions 2.120–121
 - manufacturing operations 2.122
 - master formulae 2.120
 - packaging and labelling 2.120, 2.122
 - premises and equipment 2.117–118
 - processing instructions 2.120
 - production 2.121–123
 - quality assurance 2.116
 - quality control 2.123
 - specifications 2.119–120
 - starting materials 2.118
 - unused 2.123
- investigator, definition 2.115
- irradiation 2.95–96
- ISO *see* International Organization for Standardization
- Japan, stability testing guidelines 1.58
- jewellery 2.99
- job descriptions 2.25
- kits, for radiopharmaceuticals 2.130, 2.135, 2.136
- labelling
- biological products 2.109–110
 - correct 2.64
 - evaluation of control procedures 2.142
 - expiry dates 1.115
 - GMP 2.41
 - herbal medicines 1.36
 - inspection 2.172
 - investigational products 2.120–121, 2.122
 - radiopharmaceuticals 2.134–136
 - reference substances 1.133–134
 - samples 1.166, 1.180–181
 - see also* packaging
- laboratory equipment and procedures, evaluation 2.143
- laboratory services 1.10–12, 1.154–186, 1.156, 1.159
- equipment prices 1.11
 - good practice guidelines 1.11–12, 1.162–174
 - quality control 1.110
 - safety 1.173–174, 1.179–180
 - see also drug control laboratories; national laboratories*
 - staffing 1.155–156, 1.158, 1.162, 1.164–165
- large-volume infusion solutions, testing 2.87
- large-volume parenterals, definition 2.12
- legislation
- counterfeit products 1.222, 1.224
 - imported drugs 1.211–213
 - purpose 2.159, 2.160
 - quality assurance 1.108
 - regulatory authorities 1.22–23
- less stable substances 1.44–45, 1.53
- licence-holders 1.27, 1.207
- licences 1.20–21, 1.26–27, 1.216, 1.217
- licensing 1.3, 1.19–30, 1.187
- application 2.139

- developed countries 1.160
- established products 1.27–28
- exemptions 1.20
- generic products 1.30, 1.66
- inspection 2.169
- manufacturers/distributors 1.21
- multisource products 1.30, 1.66
- new products 1.26, 1.28
- Statement of Status 1.190, 1.192
- Summary Basis of Approval 1.209
- licensing authorities
 - functions 1.19–20
 - technical competence 1.23
- limit of detection, analytical procedures 1.122, 1.123
- limit of quantitation, analytical procedures 1.122–123, 1.123
- limits of certificate by competent authority 1.191, 1.193
- linearity, analytical procedures 1.121–122, 1.123
- live organisms, handling 2.106
- long-term stability studies 1.48
- long-term use, herbal medicines 1.32–33, 1.34, 1.35
- lot *see* batch
- manufacture
 - authorization 2.139, 2.141
 - definitions 1.207, 2.12, 2.140
 - equipment *see* equipment
 - GMP 1.6, 1.108, 1.111–112
 - investigational products 2.122
 - licence 2.149
 - new products 2.143
 - process evaluation 2.142
 - quality surveillance 1.113–114
 - see also good manufacturing practices (GMP)*
- manufacturer
 - counterfeit products 1.221, 1.224
 - definitions 1.207, 2.12, 2.140
 - inspection 2.145–157
 - licensed 2.9
 - licensing 1.21
 - multisource products 1.64
 - notifiable medicinal products 1.24
 - quality control function 2.52
 - responsibilities 1.107
 - drug stability 1.4–5, 1.41, 1.50
 - responsibility 2.17, 2.59
 - sampling plans 1.184
 - of starting materials, identification 2.143
 - weak points 2.150
- markers, definition 2.125
- marketing
 - pre-marketing assessment 1.112–113
 - surveillance during 1.113–115, 1.182
- marketing authorization 2.5, 2.9, 2.149, 2.158
 - definition 2.13
 - equivalence studies 1.63, 1.69–72
 - multisource products 1.66, 1.68–69
 - see also product licences*
 - technical data 1.68–69
- master formula
 - definition 2.13
 - documentation 2.43
 - GMP 2.61–62
 - investigational products 2.120
- master record, definition 2.13
- materials
 - excipients 2.73–75
 - GMP 2.35–39, 2.195
 - see also starting materials*
- maternity homes, inspection 2.173
- mean climatic conditions 1.51–52, 1.51, 1.52
- mean kinetic temperature 1.48, 1.51
- measuring and test equipment, calibration 2.84–85
- media, sterilization 2.109
- medicinal plant material
 - definition 2.125
 - description 2.127
- medicinal plants 1.31–33
 - definition 2.125
 - see also herbal medicines*
- medium-size national laboratory 1.157–160
 - capability 1.157
 - equipment 1.158–160, 1.159
 - scope of activity 1.160–161
 - staffing 1.158
- Member States, WHO Certification Scheme 1.14, 1.188–189
- metabolite data, bioequivalence studies 1.78
- method validation/verification
 - definition 2.140
 - report 2.144
- microbiological contamination 1.119
 - clean areas 2.88

- control **2.80–81**
- limits 2.88
- monitoring 2.109
- microbiological control training
 - programme 1.16, 1.228, 1.229, **1.232–234**
 - IFPMA fellowships 1.235, **1.237**
- microbiological testing 1.158
- microorganisms
 - growth of strains 2.103
 - live 2.91
 - propagation 2.103
 - survival or multiplication 2.207
- model product
 - approach to stability assessment 2.83–84
 - definition **2.70**
- models *see* examples
- moisture content, reference substances 1.131, 1.133
- monitor, definitions **2.115, 2.203**
- monitoring
 - analytical **1.119–124**
 - basic tests programme 1.153
 - for CCPs 2.208
 - reference substances **1.132–133**
- monkeys 2.108
- monoclonal antibodies 2.103
- monographs
 - data presentation **1.120**
 - The international pharmacopoeia* **1.116–119**
- mother liquor
 - definition **2.70**
 - reuse 2.78–79
- multi-use areas 2.78
- multisource products
 - definition **1.65**
 - equivalence studies **1.69–83**
 - interchangeability 1.6, **1.62–104**
 - marketing authorization **1.69–72**
 - registration **1.62–104**
 - regulatory assessment **1.66–69**
 - see also* generic products
- “n plan”, consignment sampling **1.185, 1.186**
- narcotics 1.221
 - import controls 1.211, **1.217–219**
 - medicine counterfeiting links 1.221–222
- national drug regulation 1.2–3, **1.18–30, 1.105–115**
 - see also regulatory authorities*
- national laboratories **1.10–11, 1.154–162**
 - feasibility studies **1.161–162**
 - first-stage **1.155–156, 1.156**
 - good laboratory practices **1.162–174**
 - medium-size **1.157–160, 1.159**
 - organization and staffing **1.155–161, 1.162, 1.164–165**
 - project implementation **1.161–162**
 - see also drug control laboratories*
 - size/location **1.161**
 - specifications repertory **1.170**
 - staffing **1.155–156, 1.158, 1.162, 1.164–165**
- national requirements
 - GMP inspectorates quality systems 2.176–192
 - in vivo* equivalence studies **1.88–102, 1.89–102**
- natural forces 2.212
- new chemical entities 1.3, 1.28
- new products
 - assessment 1.21, 1.26
 - licensing 1.26
 - manufacture 2.143
 - nonproprietary names 1.113
 - tropical parasitic diseases 1.28
- nomenclature, standardization 1.113
- noncommercial institutions, quality systems principles 2.177
- nonproprietary names 1.113
- normal storage conditions **1.43**
- notification, pre-marketing assessment **1.112**
- nuclear centres and institutes 2.130, 2.131
- nursing homes, inspection 2.173
- nutrient medium 2.92
- objectives
 - basic tests **1.150**
 - drug analysis training programme **1.228**
 - The international pharmacopoeia* **1.116**
 - stability testing 1.49, **1.49–50**
 - WHO Certification Scheme 1.187–**188**
- operating conditions, deviations from normal 2.211

- operational qualification (OQ) 2.19
- optical rotation methods 1.131
- order
 - definition 2.116
 - investigational products 2.119
- organization
 - GMP 2.194
 - government control laboratories 1.164
- organizational chart 2.25, 2.59, 2.155
 - GMP inspectorate 2.180
- original samples, definition 1.178
- “other” ingredients, in medicinal plant materials 2.128
- over-the-counter drugs 2.160
 - definition 2.162
- “p plan”, consignment sampling 1.185, 1.186
- package insert 2.110
- packaging
 - batch records, investigational products 2.121
 - control procedures, evaluation 2.142
 - definition 2.13
 - drug stability 1.40, 1.47
 - excipients 2.82
 - GMP 2.44, 2.51–52, 2.64
 - herbal medicines 1.36
 - instructions
 - GMP 2.44
 - investigational products 2.120
 - investigational products 2.122
 - product information 1.133–134
 - quality assurance 1.107
 - samples 1.180–181
 - see also* labelling
- packaging materials
 - definition 2.13
 - GMP 2.36–37
 - specifications 2.41
 - storage 2.32
 - test requirements 2.55
- packing, reference substances 1.131–132
- parallel market, definition 2.163
- participation, WHO Certification Scheme 1.13, 1.188–189
- patients, education 1.42
- performance qualification (PQ) 2.19
- periodic review, GMP inspectorate 2.190–191
- personal hygiene 2.29–30, 2.98
 - see also* hygiene
- personnel
 - biological products manufacture 2.104–105
 - changes 2.150
 - in clean areas 2.98–100, 2.104–105, 2.131
 - clothing *see* clothing
 - drug analysis training programme 1.227–235
 - GMP 2.59–60, 2.194
 - health checks/health status 2.60, 2.61, 2.98, 2.104, 2.131
 - human and organizational errors 2.212
 - hygiene 2.61
 - inspection 2.17
 - investigational products 2.117
 - key 2.26–28
 - laboratories 1.155–156, 1.158, 1.162, 1.164–165, 1.227
 - qualifications and responsibilities 2.25–28
 - quality surveillance 1.109
 - safety 2.6, 2.10, 2.211
 - sampling procedures 1.179
 - in site master file 2.155–156
 - training and education in HACCP 2.204–205
 - training and expertise 2.25, 2.28–29, 2.59–60, 2.105, 2.132, 2.181–182
 - training material 2.10
 - unauthorized/untrained 2.25, 2.29, 2.30
 - vaccination 2.105
- pesticides 2.78
- pharmaceutical equivalence *see* equivalence
- pharmaceutical excipients *see* excipients
- Pharmaceutical Inspection Convention (PIC) 1.58, 2.177
- pharmaceutical inspector *see* inspector
- pharmaceutical products
 - counterfeit/spurious/substandard 2.160, 2.167, 2.174–175
 - definitions 1.207, 1.216, 2.13, 2.116, 2.161
 - HACCP methodology 2.200–212
 - hazard and risk analysis 2.200–212
 - licensed 2.9
 - moving in international commerce 2.167
 - see also* drugs

- pharmaceuticals
 - definition **2.203**
 - see also* drugs
- pharmacies
 - hospital 2.172–173
 - inspection 2.167, 2.172–173
 - retail 2.159, 2.172–173
 - wholesale outlets 2.159
- pharmacist
 - definition **2.162**
 - responsibilities 1.7, 1.17, 1.42, **1.225**
- pharmacodynamic studies 1.70, 1.72, **1.80–81**
- pharmacognostic testing, training 1.232
- pharmacokinetic abbreviations **1.103**
- pharmacopoeias 1.110, 1.170
 - The international pharmacopoeia* 1.2, 1.7–9, **1.116–149**
 - monographs 1.10, **1.116–119**, 1.150
- pharmacy-only drugs 2.160
 - definition **2.162**
- phase solubility analysis **1.129**
- photographs or videos, taken during
 - inspection visit 2.151
- physical tests, training 1.231
- pipework 2.33, 2.34, 2.108
- plant preparations **1.33**, 2.127–128
 - definition **2.125**
- poisons 1.170–171
 - definition **2.162**
- pollution, prevention 2.10
- pooled samples, definition **1.178**
- ports and stores, inspection 2.167
- positive pressure areas 2.107, 2.133
- positron emission tomography (PET)
 - centres 2.130, 2.131
- post-marketing
 - product change **1.85**
 - surveillance 2.185
- potentiometric techniques, training 1.231
- powers of enforcement, regulatory
 - authorities **1.22–23**
- pre-approval batches 2.141
 - definition **2.140**
- pre-approval inspections **2.139–145**, 2.142
- pre-marketing quality assessment **1.112–113**
- precision, analytical procedures **1.121**, 1.123
- premises
 - biological products **2.105–108**
 - clean areas **2.100–101**
 - GMP **2.30–33**, 2.60, 2.194–195
 - herbal medicines **2.126**
 - inspection 2.170
 - investigational products **2.117–118**
 - national laboratories **1.156**, **1.157–158**
 - radiopharmaceuticals **2.132–133**
 - in site master file **2.156**
 - validated cleaning procedures 2.61
- prescription-only drugs 2.160
 - definition **2.162**
- presentation, analytical procedures data **1.120**
- priority planning, provisionally registered products 1.25
- process, full description for HACCP 2.205–206
- process validation 2.19
 - excipients 2.77–78
- process-monitoring systems 2.61
- processing, sterile preparations **2.91–93**
- processing instructions, investigational products **2.120**
- processing procedures, GMP **2.50–51**, **2.63**
- processing records
 - biological preparations **2.110–111**
 - investigational products **2.121**
- procurement
 - agencies' responsibilities **1.42**
 - generic products 1.29–30
 - public sector 1.3
 - registered products 1.13
- product
 - assessment *see* assessment
 - changes 2.150
 - full description for HACCP 2.205–206
 - new **1.21**, **1.26**, **1.28**, 1.113, 2.143
 - recall *see* recall
 - testing 2.185
- product certificates **1.190–191**, 1.195–197, **1.195–199**, **1.207–208**
- product development
 - in vitro* dissolution tests **1.83–84**
 - stability testing 1.50
- product information
 - herbal medicines **1.36–37**
 - multisource products 1.69
 - WHO Certification Scheme 1.208

- product licences 1.20–21, 1.26, 1.208
see also marketing authorization
- product specification file(s)
 definition 2.116
 investigational products 2.119
- production 1.208
 biological products 2.108–109
 definition 2.13
 GMP 2.48–52, 2.63–66
 investigational products 2.121–123
 radiopharmaceuticals 2.133–134
 in site master file 2.157
- production areas
 GMP 2.32–33
 herbal medicines 2.126
- production practices, GMP 2.195
- production processes, validation 2.116
- production records,
 radiopharmaceuticals 2.136
- production sites, inspection 2.167
- prohibited drugs 2.160
 definition 2.162
- promotion
 compliance with drug laws 2.171
 herbal medicines 1.37
 laboratories 1.174
 multisource products 1.69
- protective clothing 1.174, 2.61, 2.99
- protocols
 clinical trials 1.74
 definition 2.116
- provisional registration 1.24–25
 existing medicinal products 1.24
 herbal medicines 1.29
 product screening 1.24–25
- provisional shelf-life 1.43, 1.44
- psychotropic substances 1.221
 import controls 1.211, 1.217–219
- public disclosure, quality specifications 1.110–111
- public sector, procurement 1.3
- publications, GMP inspectorate 2.189
- purity
 procurement, reference substances 1.127, 1.128, 1.129–131
see also contamination; cross-contamination
- qualifications 2.18–19
 definition 2.14
 IFPMA training fellowships 1.237–238
- laboratory staff 1.156, 1.158, 1.162, 1.164–165
see also education; training
- quality, definition 1.106–107
- quality assessment 1.106–108
 herbal medicines 1.33–34
 imported products 1.107
 legal base 1.108
 necessity for 1.106
 pre-marketing 1.112–113
- quality assurance/quality control 2.16–17
 biological preparations 2.111–112
 definitions 2.15, 2.163
 excipients 2.82–83
 GMP 2.52–56, 2.64–65, 2.194, 2.195–196
 government laboratories 1.162–174
 herbal medicines 1.32, 2.129
 IFPMA training fellowships 1.235–238
in vitro dissolution tests 1.83–84
 investigational products 2.116, 2.123
 radiopharmaceuticals 2.136–138
 sampling 1.182–183
 in site master file 2.157
 sterile products 2.87
 tests 2.55, 2.65
 training programmes 1.15–17
- quality audit 2.24–25
 definition 2.177
 excipients 2.71–72
 GMP 2.65, 2.197
- quality control areas, GMP 2.33
- quality control laboratory 1.10–12, 1.154–162, 2.65, 2.111, 2.137
 official 2.151, 2.173
- quality control unit, responsibilities 2.64–65, 2.82
- quality defects, WHO Certification Scheme 1.194
- quality management
 definition 2.15
 ISO 9000-series standards 2.5, 2.67
- quality manual 2.184, 2.187–188
 definition 2.178
- quality policy
 definition 2.15
 excipient manufacture 2.70
- quality records 2.83
- quality specifications 1.110–111
- quality surveillance
 during distribution 1.114–115
 during manufacture 1.113–114

- during marketing 1.113–115, 1.182
- expertise 1.109
- imported drugs 1.114
- national laboratories 1.10–12, 1.154–162
- quality system
 - definition 2.178
 - inspectories 2.6, 2.176–192
 - ISO 9000-series standards 2.5
 - review 2.148
- quantitation, limit of 1.122–123, 1.123
- quantitative methods, reference substances 1.125–126
- quarantine
 - definition 2.14
 - storage areas 2.31
- “r plan”, starting materials sampling 1.185–186, 1.186
- radiation
 - exposure 2.131
 - safety procedures 2.131–132
- radioactive effluents, disposal systems 2.132
- radioactivity, measuring equipment 2.134
- radionuclide generators 2.130
- radiopharmaceuticals 2.130–138
 - blood or plasma derived 2.133
 - classification 2.130
 - dispensing, packaging and transportation 2.134
 - GMP 2.4, 2.131
 - labelling 2.134–136
 - personnel 2.131–132
 - premises and equipment 2.132–133
 - production 2.133–134
 - quality assurance/quality control 2.131, 2.136–138
 - records 2.136
 - sampling 2.137–138
 - starting materials 2.134
- radiopharmacies 2.130, 2.131
- random samples, definition 1.178, 1.184–185
- randomization systems, investigational products 2.121
- range, analytical procedures 1.121–122, 1.123
- rDNA *see* recombinant DNA
- reactions, basic tests 1.151–153
- reagents 1.118, 1.170–172
 - GMP 2.38
 - safety 1.174
- real-time stability studies 1.48, 1.49–50, 1.54
- reassessment *see* inspection, follow-up
- recall
 - definition 2.162
 - records 2.149
- recall procedures 2.20–21, 2.117, 2.148, 2.171, 2.191
 - GMP 2.196
 - in site master file 2.157
 - unsatisfactory products 1.109, 1.113
- recalled products
 - GMP 2.38
 - storage 2.31
- receipt form, example 2.175–176
- recombinant DNA (rDNA) techniques 2.103, 2.107
- reconciliation, definition 2.14
- record keeping
 - equipment maintenance 2.60–61
 - HACCP 2.210
 - inspection 2.170–171
 - see also* documentation
- records
 - documentation 2.46–48
 - GMP inspectorate 2.183–184
 - retention 2.63
 - see also* batch records
- recovered materials
 - excipients 2.74
 - GMP 2.37–38
- recovery, definition 2.14
- re-evaluation dating 2.84
- reference books, inspection 2.172
- reference products 1.66
 - bioequivalence studies 1.74–75
 - choice of 1.85
- reference samples, retention 2.63
- reference sources
 - for inspector 2.166
 - see also* information sources; International Organization for Standardization (ISO), 9000 series standards
- reference standards
 - chemical and biological 2.118
 - GMP 2.39
- reference substances 1.8–9, 1.172
 - avoidance of 1.117
 - evaluation 1.127–131

- general guidelines 1.124–136, 1.124–136
 handling and distribution 1.131–135
 ICRS 1.9, 1.135–136, 1.142–148, 1.143–148
 identity 1.127, 1.128
 information exchange 1.136
 information on 1.133–134
 labelling 1.133–134
 list of available substances 1.142–148, 1.143–148
 need establishment criteria 1.125–127
 purity 1.127, 1.128, 1.129–131
 WHO Collaborating Centre address 1.143, 1.148
see also infrared reference spectra
 reflectance techniques 1.141–142
 registers, reference materials 1.172
 registration 1.3–6, 1.13, 1.17, 1.217
 clinical trials 1.21–22
 data presentation 1.120
 definition 1.208
 licence-holders 1.20
 multisource products 1.62–104
 pre-marketing assessment 1.112–113
 provisional 1.24–25
 quality specifications 1.110
 real-time studies 1.54
 stability testing 1.50
 test samples 1.52
 WHO software package 1.3
 registration certificate *see* marketing authorization; product licence
 regulation
 clinical trials 1.73–74
 herbal medicines 1.32–33, 1.34
 multisource products 1.68–69
 quality assessment 1.108–109
 regulatory actions 2.153
 regulatory authorities 1.2–3, 1.18–30, 1.206, 1.216, 2.141, 2.145, 2.149, 2.153, 2.158, 2.159
 administrative functions 2.159–160
 collaboration between 1.19, 1.66, 1.69
 counterfeit products 1.214, 1.221, 1.223
 drug control laboratories 1.162–174
 enforcement arm 2.146
 generic product licensing 1.30
 guiding principles 1.2–3, 1.18–30
 herbal medicines 1.33
 import legislation 1.211–213
 import procedures 1.210–215
 independence 1.23
 inspectorate 2.160
 licensing 1.19–21, 1.25
 licensing system 2.160
 powers of enforcement 1.22–23
 quality assurance 1.106, 1.108, 1.109–110
 quality surveillance 1.154–155
 responsibilities 1.19, 1.29, 1.66–67
 drug stability 1.41, 1.50
 multisource products 1.64, 1.66–70
 sampling procedures 1.175–186
 surveillance during marketing 1.113–115, 1.182
 technical competence 1.23
 terms of reference 1.22
 regulatory testing 2.149
 re-inspection *see* inspection, follow-up
 rejected materials
 excipients 2.74
 GMP 2.37–38, 2.66
 storage 2.31
 repeatability 1.121
 replication, tests 1.168
 reports
 inspector's 2.152
 stability testing 1.55
 WHO Expert Committee on Nonproprietary Names for Pharmaceutical Substances 1.113
 WHO Expert Committee on Specifications for Pharmaceutical Preparations 1.105–106, 1.110, 1.111, 1.163
 WHO Expert Group on Requirements for Biological Substances: Establishments and Control Laboratories 1.107–108
 WHO Scientific Group on the Bioavailability of Drugs: Principles and Problems 1.107
 reprocessed materials, GMP 2.37–38
 reprocessing, definition 2.14
 reproducibility, analytical procedures 1.121
 reserve samples, bioequivalence studies 1.78–79
 residues
 analytical methods/cleaning limits 2.73
 disposal procedures 2.61

- responsibilities
 - distributors 1.107
 - excipient manufacturer 2.68–70
 - exporting countries 1.66, 1.67
 - importers 1.107
 - individual 2.59
 - manufacturer 2.59
 - personnel 2.25–28
 - pharmacist 1.7, 1.17, 1.42, 1.225
 - procurement agencies 1.42
 - quality control unit 2.64–65
 - regulatory authorities 1.19, 1.29, 1.41, 1.50, 1.64, 1.66–70
- retention samples 1.169, 2.56
 - excipients 2.83
- returned products
 - GMP 2.38
 - investigational products 2.124
 - procedures 2.171
 - storage 2.31
- reworked materials, GMP 2.37–38
- reworking, definition 2.14
- rifampicin, bioavailability 1.64
- risk assessment 1.35
- robustness, analytical procedures 1.121, 1.123
- rodent and pest control 2.30
- rodenticides 2.78
- safety
 - herbal medicines 1.29, 1.34–35
 - laboratories 1.173–174
 - personnel 2.6, 2.10, 2.2111
 - provisionally registered products 1.24–25
 - quality assessment 1.106–107
 - sampling procedures 1.179–180
 - see also* hazard; radiation, safety procedures
- samples/sampling 1.172, 1.175–186
 - analytical procedures 1.120–121
 - analytical worksheets 1.166–167, 1.168
 - bioequivalence studies 1.77, 1.78–79
 - collection and testing 2.143–144
 - consignment acceptance 1.182–183
 - controls 1.176
 - definitions 1.177–178
 - dosage forms 1.182–183
 - during inspections 1.181, 2.151
 - general precautions 1.179–180
 - government laboratories 1.165–167
 - guidance 2.173–274
 - herbal medicines 2.129
 - independent analysis 1.14
 - methods, definition 1.177
 - packaging and labelling 1.180–181
 - plans 1.177, 1.184–186, 2.73
 - purpose of 1.175
 - quality assessment 1.163
 - radiopharmaceuticals 2.137–138
 - records 1.177–178
 - reserving 2.144
 - retention 1.169
 - stability studies 1.52–53
 - starting materials 1.183–186
 - storage 2.65
 - surveillance during marketing 1.182
 - testing 1.167–169
 - tools 1.180
 - units 1.179, 1.184–186, 1.186
- sanitation 2.18, 2.30
 - clean areas 2.87–88
 - GMP 2.61, 2.196
 - in site master file 2.156
 - written programmes 2.61
- screening, provisionally registered products 1.24–25
- seed lots, storage 2.106
- selected samples 1.178
- selectivity, analytical procedures 1.122, 1.123
- self-contained area, definition 2.14–15
- self-inspection 2.23–24, 2.145, 2.146
 - excipients 2.71–72
 - GMP 2.65, 2.197
 - report 2.24
 - in site master file 2.157
 - team 2.24
- sensitivity, analytical procedures 1.122
- separate areas 2.87
- shelf-life 1.43, 1.48–49, 1.115
 - drug stability 1.38–40, 1.41, 1.47
 - provisional 1.43, 1.44
 - storage conditions 1.55–56
 - tropical climates 1.4
- shipping/dispatch
 - definition 2.116
 - investigational products 2.123–124
- significant change, reference substances 1.133
- Single Convention on Narcotic Drugs (1961, 1972) 1.217
- sinks and drains 2.100
 - in clean areas 2.106, 2.132

- site master file 2.155–157
- small countries, drug regulation 1.18–30
- software, drug registration package 1.3
- solvents
 - infrared spectrophotometry 1.138
 - recovered 2.74
 - residual 2.76
- SOPs *see* standard operating procedures
- SPC *see* Summary of Product Characteristics
- specifications 1.110–111
 - definition 2.15
 - documentation 2.41–42
 - essential drugs 1.116
 - finished products 2.43
 - intermediate and bulk products 2.41
 - investigational products 2.119–120
 - repertory 1.170
 - shelf-life 1.49
 - starting and packaging materials 2.41
 - WHO Certification Scheme 1.204
- spectrophotometers, calibration 1.173
- spectrophotometry
 - reference substances 1.130–131
 - training 1.231
 - see also* infrared; ultraviolet spectrophotometry
- spillage 2.211
- sponsor, definition 2.116
- spore-forming organisms, handling 2.107
- stability 1.4–6, 1.37–46, 1.49
 - definition 1.42
 - less stable substances 1.44–45
 - overage 1.40
 - reference substances 1.132–133
 - supporting data 1.49
- stability studies
 - design 1.52–54
 - real-time 1.48, 1.49–50, 1.54
 - training 1.232
 - see also* accelerated stability studies; stability testing
- stability testing 1.46–61, 2.56, 2.65, 2.142
 - accelerated 1.43–44, 1.48, 1.49–50, 1.53, 1.53–54
 - analytical methods 1.54–55
 - climatic zones 1.51, 1.51, 1.52
 - excipients 2.83–84
 - GMP 2.65
 - guidelines 1.4–5, 1.57
 - herbal medicines 1.34, 2.129
 - inspection 2.150–151
 - intended market 1.51–52
 - objectives 1.49, 1.49–50
 - real-time studies 1.49, 1.54
 - registration/post-registration 1.50
 - reports 1.55
 - sample summary sheets 1.61
 - shelf-life 1.41
 - summary sheet 1.61
 - survey checklist 1.58–60
 - see also* accelerated stability studies; stability studies
- staff/staffing *see* personnel
- standard operating procedures (SOPs)
 - definitions 2.15, 2.178
 - documentation 2.46–48
 - GMP inspectorate 2.182
 - inspections 2.167, 2.174–175
 - manufacturing operations 2.108
 - radiopharmaceutical production 2.133
- standardization
 - analytical procedures 1.127
 - drug nomenclature 1.113
- standards
 - GMP 1.188
 - The international pharmacopoeia* 1.2
 - see also* International Organization for Standardization (ISO), 9000 series standards
- starting materials 1.217
 - definition 2.15
 - excipients 2.74
 - GMP 2.35–36, 2.58–85, 2.63
 - herbal medicines 2.126–127
 - importation 1.214
 - investigational products 2.118
 - quality control 2.54, 2.82
 - radiopharmaceuticals 2.134
 - sampling 1.183–186
 - specifications 2.41, 2.108
 - test requirements 2.55
- Statement of Licensing Status 1.190, 1.192, 1.200–201
- statistical analysis, bioequivalence studies 1.79–80, 1.104
- sterile products 2.86–102
 - active pharmaceutical ingredients 2.64
 - enclosed areas 2.60
 - excipients 2.80
 - finishing 2.102
 - manufacture 2.88–93
 - processing 2.91–93

- sterility testing 2.87
- sterilization **2.93–94**
 - by dry heat **2.95**
 - by filtration **2.97–98**
 - by gases and fumigants **2.96–97**
 - by heat **2.94–95**
 - by moist heat **2.95**
 - by radiation **2.95–96**
 - records 2.94
 - SOPs 2.100
 - validation of methods 2.109
- sterilizing equipment, validation 2.117
- stocks, time-expired 1.5, **1.40**, 2.171
- storage
 - defined instructions **1.43**
 - degradation dangers 1.4
 - drug stability 1.38–39, 1.41, 1.47, 1.53
 - facilities 2.31–32, 2.167, 2.170
 - GMP **2.65**
 - herbal medicines **2.126**
 - imported products 1.211, **1.215**
 - normal conditions **1.43**
 - outdoor 2.74
 - quality assurance 1.107, 1.108–109, 1.115
 - reagents 1.171–172
 - reference substances **1.131–132**
 - shelf-life **1.55–56**
- subjects, bioequivalence studies 1.75, 1.77
- Summary Basis of Approval **1.209**
- Summary of Product Characteristics (SPC) **1.209**
- supplementary guidelines *see* guidelines
- suppliers
 - audits and approval 2.25
 - identification 2.143
 - new 2.143
- supply systems
 - drug stability 1.42
 - quality assurance **1.105–115**
- supporting stability data **1.49**
- surveillance
 - national laboratories **1.154–162**, 1.156, **1.159**
 - sampling **1.182**
 - testing 2.149
 - see also* quality surveillance
- surveys, WHO Model List of Essential Drugs 1.55, 1.58–60
- syllabuses, control training programmes 1.16–17
- teaching, training programmes 1.229–230
- technical aspects, drug regulation 2.160
- technical competence, licensing
 - authorities **1.23**
- technical data, multisource products **1.68–69**
- temperature
 - mean kinetic **1.48**, 1.51–52
 - stability testing 1.51, **1.51–54**, 1.52, 1.53
 - storage 1.132
- temperature recording devices 2.72
- tenders 1.29–30, 1.193
- teratogenicity, herbal substances 1.29, 1.33
- terminal sterilization 2.93, **2.94–97**
 - see also* sterilization
- terminally sterilized products **2.90–91**
- terms of reference, national regulatory
 - authorities 1.22
- test requirements, quality control 2.55
- test samples, stability studies **1.52–53**
- tests
 - documentation of procedures 2.41–42
 - dosage forms **1.117–119**
 - errors 1.168
 - evaluation **1.169**
 - samples **1.167–168**
 - therapeutic equivalence **1.72–83**
 - see also* analytical procedures; basic tests; stability testing
- therapeutic equivalence **1.65**, 1.67
 - generic products 1.30
 - in vivo* studies 1.67–68
 - marketing authorization 1.69–70
 - see also* interchangeability
- therapeutically active substances 1.29
- thin-layer chromatography (TLC)
 - 1.117–119, 1.126, **1.130**, 1.157
 - see also* chromatography; gas-liquid chromatography (GLC)
- time-expired stock 1.5, **1.40**, 2.171
- titrimetric methods
 - reference substances **1.131**
 - training 1.231
- TLC *see* thin-layer chromatography
- toilet facilities 2.60
- tools, sampling **1.180**
- toxicity, herbal products 1.29, 1.32–35
- toxins 2.207
- traditional medicine *see* herbal medicines

- trainees, drug analysis training
 programme 1.229, 1.230
 training 1.227–238
 drug analysis programme 1.227–235,
 1.231–232
 IFPMA fellowships 1.235–238
 import procedures 1.215
 laboratory services staff 1.156, 1.162
 personnel 2.28–29, 2.204–205
 quality control programmes 1.15–17
 see also education; qualifications
 transit
 imported drugs 1.211
 quality assurance 1.107
 treaties, international drug control 1.217
 tropical climates
 product stability 1.4–6, 1.38, 1.40
 volatile solvents 1.119
 tropical parasitic diseases 1.28
 tuberculosis, testing for 2.105
- ultraviolet irradiation 2.95
 ultraviolet spectrophotometry 1.125,
 1.126, 1.127, 1.130
 unauthorized markets 2.165
 definition 2.163
 inspection 2.173
 UNDCP *see* United Nations International
 Drug Control Programme
 unhygienic practices 2.60, 2.61
 uniformity, sampling materials 1.176
 United Nations International Drug
 Control Programme (UNDCP)
 1.211, 1.222
 United States of America (USA)
 in vivo equivalence study requirements
 1.89, 1.89–102
 legal status of investigational
 products 2.113
 unsatisfactory products, recall 1.109,
 1.113
 use, intended 2.206
 utilization period, definition 1.44,
 1.49
- vaccines 2.91, 2.103
 BCG 2.105
 killed 2.107
 requirements 2.104
 validation
 analytical procedures 1.8, 1.78, 1.119–
 124
 definitions 2.15, 2.203
 GMP 2.18–19, 2.196
 and HACCP 2.201
 see also process validation
 vegetable drug, definition 2.125
 verification
 basic tests 1.153
 definition 2.203
 HACCP procedures 2.209–210
 victims, counterfeit products 1.220
 visitors 2.25, 2.29, 2.30
 visual records of inspection 2.151
 volatile solvents 1.119, 1.131
 voucher specimens, herbal medicines
 1.33
- warehouse/store, inspection 2.170
 washing
 facilities 2.60, 2.100
 SOPs 2.100
 written procedure 2.99
 waste materials
 disposal procedures 2.61
 GMP 2.39
 water and water systems
 in clean areas 2.102
 in excipient manufacture 2.81–82
 in manufacture of pharmaceutical
 products 2.35
 monitoring/testing 2.87, 2.92
 quality standard 2.61
 weighing areas, GMP 2.32
 wholesalers 1.225, 2.159
 withdrawals procedure 2.191
 see also recall
 within-laboratory variation 1.121
 workers *see* personnel
 working conditions
 clean areas 2.106
 hygienic 2.60
 workshops
 counterfeit drugs 1.15
 herbal medicines regulation 1.32
 World Customs Organization
 1.211
 World Health Assembly (WHA)
 GMP inception 2.8–9
 herbal medicines 1.31–32
 quality assurance concerns 1.1, 1.12,
 2.1–2
 WHO Certification Scheme 1.188,
 1.209–210

INDEX

- World Health Organization (WHO)
 Certification Scheme *see* Certification Scheme
 pharmaceuticals newsletter 1.189
- Requirements for Biological Substances 2.104
 Revised Drug Strategy 2.1
wrist-watches 2.99